Levodopa-induced Dyskinesia: A Brief Review of the Ongoing Clinical Trials

Kang, Woojin; Kim, Esther; Bédard, Dominique; Belliveau, Sébastien; Frouni, Imane; Kwan, Cynthia

doi:10.2217/nmt-2021-0051

Cited by 4 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, over the disease's progression, the increasing loss of dopaminergic neurons and the chronic exposure to dopaminergic drugs lead to decayed long-duration and increased short-duration responses to L-Dopa (i.e., abnormal dopamine synthesis, storage, release, and buffering) [9]. As a result of these changes, patients manifest motor complications, such as wearing-off phenomenon, motor fluctuations [1], unpredictable OFF times [10,11], and L-Dopa-induced dyskinesias (LIDs) [12], which all depend on the fluctuation of L-Dopa plasmatic levels [9,13,14]. The progressive narrowing of the L-Dopa therapeutic window leads patients to take higher drug doses, also increasing the administration intervals.…”

Section: Hunting Biomarkers For Diagnosis and Follow-up In Pdmentioning

confidence: 99%

“…Further complicating this issue, it has been observed that the pharmacokinetic effects of L-Dopa become non-linear in a more advanced stage of the disease, being responsible for several complications. Although early-stage patients benefit from oral L-Dopa administration, more advanced patients experience a wearing-off phenomenon, motor fluctuations [1], unpredictable OFF times [10,11], and LIDs [12], which all depend on the fluctuation of L-Dopa plasmatic levels [9,13,14]. Hence, advanced-stage PD patients would benefit from advanced therapies designed to overcome the drawbacks of L-Dopa pharmacokinetic effects [54] by continuous infusion of the drug.…”

Section: Clinical Prospects In Pdmentioning

confidence: 99%

See 1 more Smart Citation

Wearable Electrochemical Sensors in Parkinson’s Disease

Asci

Vivacqua

Zampogna

et al. 2022

Sensors

View full text Add to dashboard Cite

Parkinson’s disease (PD) is a neurodegenerative disorder associated with widespread aggregation of α-synuclein and dopaminergic neuronal loss in the substantia nigra pars compacta. As a result, striatal dopaminergic denervation leads to functional changes in the cortico-basal-ganglia-thalamo-cortical loop, which in turn cause most of the parkinsonian signs and symptoms. Despite tremendous advances in the field in the last two decades, the overall management (i.e., diagnosis and follow-up) of patients with PD remains largely based on clinical procedures. Accordingly, a relevant advance in the field would require the development of innovative biomarkers for PD. Recently, the development of miniaturized electrochemical sensors has opened new opportunities in the clinical management of PD thanks to wearable devices able to detect specific biological molecules from various body fluids. We here first summarize the main wearable electrochemical technologies currently available and their possible use as medical devices. Then, we critically discuss the possible strengths and weaknesses of wearable electrochemical devices in the management of chronic diseases including PD. Finally, we speculate about possible future applications of wearable electrochemical sensors in PD, such as the attractive opportunity for personalized closed-loop therapeutic approaches.

show abstract

Section: Hunting Biomarkers For Diagnosis and Follow-up In Pdmentioning

confidence: 99%

Section: Clinical Prospects In Pdmentioning

confidence: 99%

Wearable Electrochemical Sensors in Parkinson’s Disease

Asci

Vivacqua

Zampogna

et al. 2022

Sensors

View full text Add to dashboard Cite

show abstract

“…Even the dopamine (DA) precursor levodopa, considered to be the gold-standard for treatment of motor dysfunction and used for over 50 years, elicits a wide range of efficacy [1,2]. Additionally, levodopa-induced dyskinesia (LID), the common side effect of long-term levodopa therapy is estimated to occur in up to 90% of individuals with PD within 10 years of treatment [3][4][5]. Accordingly, efforts continue to identify additional therapeutic options for PD.…”

Section: Introductionmentioning

confidence: 99%

Advancing Age and the rs6265 BDNF SNP are Permissive to Graft-induced Dyskinesias in Parkinsonian Rats

Steece-Collier,

Mercado,

Szarowicz

et al. 2024

Preprint

View full text Add to dashboard Cite

The rs6265 single nucleotide polymorphism (SNP) in the gene for brain-derived neurotrophic factor is a common variant that alters therapeutic outcomes for individuals with Parkinson’s disease (PD). We previously investigated the effects of this SNP on the experimental therapeutic approach of neural grafting, demonstrating that young adult parkinsonian rats carrying the variant Met allele exhibited enhanced graft function compared to wild-type rats, and also exclusively developed aberrant graft-induced dyskinesias (GID). Aging is the primary risk factor for PD and reduces graft efficacy. Here we investigated whether aging interacts with this SNP to further alter cell transplantation outcomes. We hypothesized that aging would dampen enhancement of graft function associated with this genetic variant and exacerbate GID in all grafted subjects. Unexpectedly, beneficial graft function was maintained in aged rs6265 subjects. However, aging was permissive to GID induction, regardless of genotype, with the greatest incidence and severity found in rs6265 expressing animals.

show abstract